Lucas CJ - Search Results

1

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

Lucas CJ, Martin JH. Lucas CJ, et al. J Clin Pharmacol. 2017 Oct;57 Suppl 10:S78-S98. doi: 10.1002/jcph.937. J Clin Pharmacol. 2017. PMID: 28921641 Review.

2

Medicines optimisation in older people: Taking age and sex into account.

Lucas C, Byles J, Martin JH. Lucas C, et al. Maturitas. 2016 Nov;93:114-120. doi: 10.1016/j.maturitas.2016.06.021. Epub 2016 Jun 26. Maturitas. 2016. PMID: 27506133 Review.

3

Pill testing at music festivals: can we do more harm?

Schneider J, Galettis P, Williams M, Lucas C, Martin JH. Schneider J, et al. Intern Med J. 2016 Nov;46(11):1249-1251. doi: 10.1111/imj.13250. Intern Med J. 2016. PMID: 27813348 No abstract available.

4

Predicting drug interactions in addiction treatment.

Lucas CJ, Patel J, Martin JH. Lucas CJ, et al. Intern Med J. 2017 Aug;47(8):872-878. doi: 10.1111/imj.13500. Intern Med J. 2017. PMID: 28782217

5

Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

Martin JH, Schneider J, Lucas CJ, Galettis P. Martin JH, et al. Among authors: lucas cj. Clin Pharmacokinet. 2018 May;57(5):539-545. doi: 10.1007/s40262-017-0599-0. Clin Pharmacokinet. 2018. PMID: 28921125

6

Comment on a paper by Dupoiron et al. "A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone- naloxone (up to 160/80 mg daily) versus oxycodone PR".

Patel J, Martin JH, Lucas CJ. Patel J, et al. Among authors: lucas cj. Eur J Pain. 2017 Nov;21(10):1772-1773. doi: 10.1002/ejp.1098. Eur J Pain. 2017. PMID: 28990731 No abstract available.

7

Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.

Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, Martin JH. Lucas CJ, et al. Clin Ther. 2018 Sep;40(9):1442-1447. doi: 10.1016/j.clinthera.2017.12.008. Epub 2018 Jan 6. Clin Ther. 2018. PMID: 29317112

8

Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

Martin JH, Schneider J, Lucas CJ, Galettis P. Martin JH, et al. Among authors: lucas cj. Clin Pharmacokinet. 2018 May;57(5):645. doi: 10.1007/s40262-018-0633-x. Clin Pharmacokinet. 2018. PMID: 29468560

9

Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects.

Dryburgh LM, Bolan NS, Grof CPL, Galettis P, Schneider J, Lucas CJ, Martin JH. Dryburgh LM, et al. Among authors: lucas cj. Br J Clin Pharmacol. 2018 Nov;84(11):2468-2476. doi: 10.1111/bcp.13695. Epub 2018 Aug 1. Br J Clin Pharmacol. 2018. PMID: 29953631 Free PMC article.

10

The pharmacokinetics and the pharmacodynamics of cannabinoids.

Lucas CJ, Galettis P, Schneider J. Lucas CJ, et al. Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7. Br J Clin Pharmacol. 2018. PMID: 30001569 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters